Hormonal

Abaloparatide

Also known as: Tymlos, BA058

FDA Approved
Share:

Key Facts: Abaloparatide

Category
Hormonal
FDA Status
FDA Approved
Clinical Status
FDA Approved - Osteoporosis in postmenopausal women and men at high risk for fracture (male indication added Dec 2022)
Administration
Subcutaneous injection daily
Typical Dose
80 mcg daily
Frequency
Once daily
Duration
Maximum 2 years (same lifetime limit as teriparatide)
Also Known As
Tymlos, BA058

Mechanism of Action

Abaloparatide hits the same target as teriparatide, the PTH type 1 receptor (PTHR1), but it was engineered to favor a specific receptor conformation (the RG-bound state) that produces a more transient signal. The idea, supported by preclinical data, is that this shorter signaling burst pushes osteoblast-driven bone formation while triggering less of the osteoclast-driven resorption that PTH-type drugs also switch on. In practice that can mean a wider anabolic window and somewhat less hypercalcemia than teriparatide, though it is the same overall receptor and pathway. It is still given as a once-daily subcutaneous injection, relying on the same pulsatile dosing logic that makes anabolic PTH therapy work.

Research Summary

The core human evidence is the ACTIVE phase 3 trial, which randomized more than 2,400 postmenopausal women to abaloparatide, placebo, or open-label teriparatide for 18 months. Abaloparatide cut new vertebral fractures by about 86 percent and nonvertebral fractures by about 43 percent versus placebo, and reduced major osteoporotic fractures more than teriparatide did in that comparison. A cardiovascular safety analysis from ACTIVE was reassuring, though transient increases in heart rate are a known on-label effect of the class. The ATOM trial later supported the 2022 approval in men by showing bone-density gains comparable to those seen in women. Because abaloparatide is PTHR1-based like teriparatide, it originally carried the same rat-osteosarcoma-derived boxed warning and lifetime-use caution, and label thinking on that class evolved alongside the teriparatide updates. This is solid RCT-backed evidence, not preliminary research.

Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosing

Community experience

Common Dose

80 mcg daily

Range

80 mcg daily

Frequency

Once daily

PTHrP analog for osteoporosis. Similar to teriparatide but different binding profile.

Research Dosing

Scientific studies

FDA-approved dosing

Doses from Studies

Duration

Maximum 2 years (same lifetime limit as teriparatide)

Administration

Subcutaneous injection daily

Timing & Administration

Best Time to Take

Morning or as directed

Follow recommended protocol

Food Recommendation

With or without food

Why This Timing?

Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Hypercalciuria (11%)
  • Dizziness (10%)
  • Nausea (8%)
  • Palpitations (5%)
  • Injection site reactions
  • Orthostatic hypotension
  • Osteosarcoma risk in rats
  • FDA approved (Tymlos)

References

Research This Peptide Further

Frequently Asked Questions

What does Abaloparatide do?

Abaloparatide (brand name Tymlos) is a synthetic 34-amino-acid analog of parathyroid hormone-related protein (PTHrP), and like teriparatide it is an anabolic osteoporosis drug that builds new bone. The FDA approved it in April 2017 for postmenopausal women at high fracture risk, and in December 2022 added men with osteoporosis at high fracture risk. It is the second drug in its class and was designed to lean harder on bone formation with less of the bone-breakdown and calcium-spike baggage.

How does Abaloparatide work?

Abaloparatide hits the same target as teriparatide, the PTH type 1 receptor (PTHR1), but it was engineered to favor a specific receptor conformation (the RG-bound state) that produces a more transient signal. The idea, supported by preclinical data, is that this shorter signaling burst pushes osteoblast-driven bone formation while triggering less of the osteoclast-driven resorption that PTH-type drugs also switch on. In practice that can mean a wider anabolic window and somewhat less hypercalcemia than teriparatide, though it is the same overall receptor and pathway. It is still given as a once-daily subcutaneous injection, relying on the same pulsatile dosing logic that makes anabolic PTH therapy work.

Is Abaloparatide FDA approved?

Yes, Abaloparatide is FDA approved. FDA Approved - Osteoporosis in postmenopausal women and men at high risk for fracture (male indication added Dec 2022)

What are the side effects of Abaloparatide?

Reported side effects include: Hypercalciuria (11%), Dizziness (10%), Nausea (8%), Palpitations (5%), Injection site reactions. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Abaloparatide?

Community-reported common dose: 80 mcg daily (Once daily). Range: 80 mcg daily. Administration: Subcutaneous injection daily. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Abaloparatide or used in similar applications.

Oxytocin

FDA

Oxytocin is a 9-amino-acid hormone made in the hypothalamus, famous as the chemistry behind labor contractions, breastfeeding, and social bonding. As an injectable drug it is FDA-approved to induce labor and control postpartum bleeding, but the intranasal 'love hormone' versions sold for trust, anxiety, and autism are experimental and the human results are genuinely mixed. The hype runs well ahead of the evidence.

Hormonal

Gonadorelin

FDA

Gonadorelin is a synthetic copy of natural GnRH (gonadotropin-releasing hormone), a 10-amino-acid peptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that tells the pituitary to release LH and FSH. It is FDA-approved for evaluating pituitary function and has historical use in inducing ovulation. In the peptide world it is mostly used off-label to keep the testes working during testosterone replacement, and the catch is that timing matters enormously: pulse it and you stimulate, give it continuously and you shut the system down.

Hormonal

Leuprolide

FDA

Leuprolide (brand name Lupron) is a synthetic GnRH agonist, a modified peptide about 20 times more potent than natural GnRH, and it is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The clever part is counterintuitive: it works by overstimulating the GnRH system so hard that the pituitary shuts down sex hormone production. It is a real, long-established prescription drug, not a research peptide, and it carries meaningful side effects from the low-hormone state it creates.

Hormonal

Desmopressin

FDA

Desmopressin (dDAVP) is a synthetic tweak of the natural hormone vasopressin, redesigned to keep the water-retaining effect while dropping most of the blood-pressure effect. It is a long-established FDA-approved drug used for central diabetes insipidus, bedwetting and nocturia, and certain bleeding disorders like von Willebrand disease and mild hemophilia A. This is settled medicine, not an experimental peptide, and its main real-world danger is straightforward: it can drop your blood sodium dangerously low if you drink too much fluid on it.

Hormonal

Octreotide

FDA

Octreotide is a synthetic eight-amino-acid mimic of the natural hormone somatostatin, the body's main 'off switch' for hormone secretion. It shuts down excess growth hormone, so it is a frontline FDA-approved drug for acromegaly, and it also tames the flushing and diarrhea of hormone-secreting carcinoid and other neuroendocrine tumors. This is real, approved medicine with decades of clinical data behind it, sold as Sandostatin (injectable, since 1988), Sandostatin LAR (monthly depot), and Mycapssa (oral capsule, approved 2020).

Hormonal

Lanreotide

FDA

Lanreotide is an eight-amino-acid somatostatin analog, a close cousin of octreotide, given as a long-acting deep-injection gel (Somatuline Depot/Autogel) usually once a month. It is FDA-approved for acromegaly and for gastroenteropancreatic neuroendocrine tumors, and it carries an approval for carcinoid syndrome. It is established prescription medicine, not an experimental compound.

Hormonal

Want updates on Abaloparatide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.